Table 3.
Univariate analysis of the association between clinicopathologic parameters or OCT2 level and chemotherapeutic response in the entire cohort
| Variables | No. | Res. (%) | Non-res. (%) | P-value |
|---|---|---|---|---|
| Age (years) | ||||
| ≥ 60 | 38 | 22 (58) | 16 (42) | 0.77 |
| < 60 | 18 | 9 (50) | 9 (50) | |
| Sex | ||||
| Man | 33 | 20 (61) | 13 (39) | 0.42 |
| Woman | 23 | 11 (48) | 12 (52) | |
| Tumor localization1 | ||||
| Proximal | 26 | 14 (54) | 12 (46) | 1.00 |
| Non-proximal | 30 | 17 (57) | 13 (43) | |
| Laurén classification2 | ||||
| Intestinal | 11 | 9 (82) | 2 (18) | 0.09 |
| Non-intestinal | 45 | 22 (49) | 23 (51) | |
| Histologic grade2 | ||||
| G1/G2 | 11 | 9 (82) | 2 (18) | 0.09 |
| G3/G4 | 45 | 22 (49) | 23 (51) | |
| HER2 status3 | ||||
| Positive | 2 | 1 (50) | 1 (50) | 1.00 |
| Negative | 45 | 24 (53) | 21 (47) | |
| NAC regimen | ||||
| S-1/CDDP | 28 | 17 (61) | 11 (39) | 0.59 |
| PTX/CDDP | 28 | 14 (50) | 14 (50) | |
| OCT2 level | ||||
| High | 41 | 26 (63) | 15 (37) | 0.07 |
| Low | 15 | 5 (33) | 10 (67) |
1
Even when diffuse/entire vs. non-diffuse/entire was analyzed instead of proximal vs. non-proximal, a significant association was not detected;
2
Laurén classification and histologic grade data showed the same pattern;
3
Human epidermal growth factor receptor type 2 (HER2) was evaluable in 47 of the 56 patients.
OCT2: organic cation transporter 2; Res.: responder; Non-res.: non-responder; NAC: neoadjuvant chemotherapy; CDDP: cisplatin; PTX: paclitaxel.